Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-Lynch preventive dendritic cell vaccination study
NL-OMON61461Phase 2Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2026
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in hereditary nonpolyposis colorectal cancer (HNPCC), sponsored by Radboud University Medical Center. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)
Beyond the preview
Go deeper on NL-OMON61461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61461.